Effect of Exogenous Melatonin on Morphological Features of B16 Melanoma in Mice
- Authors: Areshidze D.A.1, Mnikhovich M.V.1, Deev R.V.1, Kozlova M.A.1, Anurkina A.I.1, Mishchenko D.V.2, Sashenkova T.Е.2, Turchin A.N.3
-
Affiliations:
- Petrovsky National Research Centre of Surgery
- Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences
- Mechnikov North-Western State Medical University
- Issue: Vol 163, No 1 (2025)
- Pages: 17-27
- Section: Original Study Articles
- Submitted: 05.11.2024
- Accepted: 31.01.2025
- Published: 14.05.2025
- URL: https://j-morphology.com/1026-3543/article/view/641601
- DOI: https://doi.org/10.17816/morph.641601
- EDN: https://elibrary.ru/KEIGXT
- ID: 641601
Cite item
Abstract
BACKGROUND: Constant illumination over a long period of time suppresses the hormone-synthesizing function of the pineal gland, leading to a decrease in melatonin levels and, consequently, to accelerated aging of the body, increased incidence of age-associated pathologies, including neoplasms, and shortened life expectancy. Melatonin has a pronounced antitumor effect. In particular, its antiproliferative effect is highlighted. Melanoma is one of the most malignant neoplasms in humans, originating from melanin-producing cells. In recent years, the proportion of older patients among patients with melanoma has been increasing, which makes it possible to classify this disease as age-associated. There is evidence that melatonin deficiency and the resulting disruption of the body’s circadian rhythms is one of the factors contributing to the development of melanoma.
AIM: To investigate the effect of exogenous melatonin on the morphological features of B16 melanoma in mice.
METHODS: The study was conducted on male hybrid mice of the BDF1 line (n = 60) at the age of 8 weeks, weighing 21–22 g. All animals received subcutaneous transplantation of B16/F10 melanoma in suspension. The mice were further divided into two groups, control and experimental. Animals of the experimental group were administered melatonin (Sigma, USA) at a dose of 5 mg/kg intragastrically from the first day of the study. On the 15th day after tumor transplantation, the tumor itself, as well as the lungs and liver, were removed. Pathomorphological examination of the tumor was performed, and the presence of lung and liver metastases was determined. Area of necrosis was measured on histological slides of the tumor stained with hematoxylin and eosin, and the nuclear-cytoplasmic ratio in tumor cells was calculated by measuring the cross-sectional area of nuclei and the cross-sectional area of cells. Graphing and statistical analysis of the results were performed using GraphPad Prism v8.41 (USA).
RESULTS: It was found that melatonin administration during the studied period reduced the mortality of mice with melanoma, decreased the incidence of tumor metastasis and tumor size. In addition, in melanomas of the experimental group of mice, signs of tumor regression in the form of foci of dystrophic and alterative changes were visualized, as well as a statistically significant increase in the area of tumor necrosis.
CONCLUSION: The present study showed that exogenous melatonin has a pronounced antitumor effect against B16 melanoma in mice. The obtained results allow planning more thorough and multidisciplinary studies for in-depth investigation of the mechanisms of melatonin antitumor effect.
Keywords
Full Text

About the authors
David A. Areshidze
Petrovsky National Research Centre of Surgery
Author for correspondence.
Email: labcelpat@mail.ru
ORCID iD: 0000-0003-3006-6281
SPIN-code: 4348-6781
Cand. Sci. (Biology)
Russian Federation, MoscowMaxim V. Mnikhovich
Petrovsky National Research Centre of Surgery
Email: mnichmaxim@yandex.ru
ORCID iD: 0000-0001-7147-7912
SPIN-code: 6975-6677
Cand. Sci. (Medicine)
Russian Federation, MoscowRoman V. Deev
Petrovsky National Research Centre of Surgery
Email: romdey@gmail.com
ORCID iD: 0000-0001-8389-3841
SPIN-code: 2957-1687
Cand. Sci. (Medicine), Associate Professor
Russian Federation, MoscowMaria A. Kozlova
Petrovsky National Research Centre of Surgery
Email: ma.kozlova2021@outlook.com
ORCID iD: 0000-0001-6251-2560
SPIN-code: 5647-1372
Cand. Sci. (Biology)
Russian Federation, MoscowAnna I. Anurkina
Petrovsky National Research Centre of Surgery
Email: anyaaai1925@gmail.com
ORCID iD: 0009-0003-0011-1114
SPIN-code: 9812-3412
Russian Federation, Moscow
Denis V. Mishchenko
Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences
Email: mdv@icp.ac.ru
ORCID iD: 0000-0003-3779-3211
SPIN-code: 4213-3318
Cand. Sci. (Biology)
Russian Federation, ChernogolovkaTatyana Е. Sashenkova
Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences
Email: tsashen52@mail.ru
ORCID iD: 0000-0002-2753-979X
Russian Federation, Chernogolovka
Anton N. Turchin
Mechnikov North-Western State Medical University
Email: ktogrb@yandex.ru
ORCID iD: 0009-0008-5302-5769
Russian Federation, Saint Petersburg
References
- Anisimov VN. Light pollution, reproductive function and cancer risk. Neuro Endocrinol Lett. 2006;27(1–2):35–52.
- Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8(12):1065–1066. doi: 10.1016/S1470-2045(07)70373-X
- Pauley SM. Lighting for the human circadian clock: recent research indicates that lighting has become a public health issue. Med Hypotheses. 2004;63(4):588–596. doi: 10.1016/j.mehy.2004.03.020
- Stevens RG. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int J Epidemiol. 2009;38(4):963–970. doi: 10.1093/ije/dyp178
- Arushanian EB, Naumov SS. A wide range of pharmacological properties of melatonin. Reviews on Clinical Pharmacology and Drug Therapy. 2021;19(1):103–106. (In Russ.) doi: 10.17816/RCF191103-106 EDN: XKUIWB
- Sato K, Meng F, Francis H, et al. Melatonin and circadian rhythms in liver diseases: functional roles and potential therapies. J Pineal Res. 2020;68(3):e12639. doi: 10.1111/jpi.12639
- Zuev VA, Trifonov NI, Linkova NS, Kvetnaia TV. Melatonin as a molecular marker of age-related pathologies. Advances in Gerontology. 2017;30(1):62–69. (In Russ.) EDN: YHTMRF
- Anisimov VN, Vinogradova IA. Light regime, biorythms and organism aging. Aesthetic Medicine Bulletin. 2011;10(1):42–51. (In Russ.) EDN: OEVILV
- Anisimov VN. Light, aging, and cancer. Priroda. 2018;(6):19–22. (In Russ.) EDN: XQNOMP
- Kvetnaia TV, Polyakova VO, Proshaev KI, et al. Melatonin as a marker of ageing and age-associated diseases. RUDN Journal of Medicine. 2012;(S7):125–126. (In Russ.) EDN: RCADUR
- Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, et al. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351(2):152–166. doi: 10.1016/j.mce.2012.01.004
- Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;85(3):335–353. doi: 10.1016/j.pneurobio.2008.04.001
- Malishevskaya NP, Sokolova AV, Demidov LV. The incidence of skin melanoma in the Russian Federation and federal districts. Medical Council. 2018;(10):161–165. (In Russ.) doi: 10.21518/2079-701X-2018-10-161-165 EDN: UUDAMY
- Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46(2):270–283. doi: 10.1016/j.ejca.2009.10.032
- Erkenova FD, Puzin SN. Statistics of melanoma in Russia and Europe. Medical and Social Expert Evaluation and Rehabilitation. 2020;23(1):44–52. (In Russ.) doi: 10.17816/MSER34259 EDN: WIAAEF
- de Assis LVM, Moraes MN, Mendes D, et al. Loss of Melanopsin (OPN4) leads to a Faster cell cycle progression and growth in murine melanocytes. Curr Issues Mol Biol. 2021;43(3):1436-1450. doi: 10.3390/cimb43030101
- Lubov JE, Cvammen W, Kemp MG. The impact of the circadian clock on skin physiology and cancer development. Int J Mol Sci. 2021;22(11):6112. doi: 10.3390/ijms22116112
- Mubashshir M, Ahmad N, Sköld HN, Ovais M. An exclusive review of melatonin effects on mammalian melanocytes and melanoma. Exp Dermatol. 2023;32(4):324–330. doi: 10.1111/exd.14715
- Jansen R, Osterwalder U, Wang SQ, et al. Photoprotection: part II. Sunscreen: development, efficacy, and controversies. J Am Acad Dermatol. 2013;69(6):867.e1–14. doi: 10.1016/j.jaad.2013.08.022
- Slominski AT, Hardeland R, Zmijewski MA, et al. Melatonin: a cutaneous perspective on its production, metabolism, and functions. J Invest Dermatol. 2018;138(3):490–499. doi: 10.1016/j.jid.2017.10.025
- Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71(16):2997–3025. doi: 10.1007/s00018-014-1579-2
- Alvarez-Artime A, Cernuda-Cernuda R, Francisco-Artime-Naveda, et al. Melatonin-induced cytoskeleton reorganization leads to inhibition of melanoma cancer cell proliferation. Int J Mol Sci 2020;21(2):548. doi: 10.3390/ijms21020548
- Cutando A, López-Valverde A, Arias-Santiago S, et al. Role of melatonin in cancer treatment. Anticancer Res. 2012;32(7):2747–2753.
- Treshchalina EM, Zhukova OS, Gerasimova GK, et al. Methodological recommendations for the preclinical study of the antitumor activity of drugs. In: Guidelines for conducting preclinical studies of drugs. Pt. 1. Moscow: Grif i K; 2012. P:640–656. (In Russ.)
- Broeke J, Pérez JMM, Pascau J. Image Processing with ImageJ. Birmingham: Packt Publishing; 2015.
- Franco PIR, do Carmo Neto JR, Milhomem AC, et al. Antitumor effect of melatonin on breast cancer in experimental models: a systematic review. Biochim Biophys Acta Rev Cancer. 2023;1878(1):188838. doi: 10.1016/j.bbcan.2022.188838
- Fathizadeh H, Mirzaei H, Asemi Z. Melatonin: an anti-tumor agent for osteosarcoma. Cancer Cell Int. 2019;19:319. doi: 10.1186/s12935-019-1044-2
- Shen D, Ju L, Zhou F, et al. The inhibitory effect of melatonin on human prostate cancer. Cell Commun Signal. 2021;19(1):34. doi: 10.1186/s12964-021-00723-0
- Su SC, Hsieh MJ, Yang WE, et al. Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res. 2017;62(1). doi: 10.1111/jpi.12370
- Martínez-Campa C, Álvarez-García V, Alonso-González C, et al. Melatonin and its role in the epithelial-to-mesenchymal transition (EMT) in cancer. Cancers (Basel). 2024;16(5):956. doi: 10.3390/cancers16050956
- Lu KH, Lin CW, Hsieh YH, et al. New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence. Cancer Metastasis Rev. 2020;39(1):303–320. doi: 10.1007/s10555-020-09845-2
- Wang L, Wang C, Choi WS. Use of melatonin in cancer treatment: where are we? Int J Mol Sci. 2022;23(7):3779. doi: 10.3390/ijms23073779
- Blask DE, Dauchy RT, Sauer LA, Krause JA. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis. 2004;25(6):951–960. doi: 10.1093/carcin/bgh090
- Laothong U, Pinlaor P, Hiraku Y, et al. Protective effect of melatonin against Opisthorchis viverrini-induced oxidative and nitrosative DNA damage and liver injury in hamsters. J Pineal Res. 2010;49(3):271–282. doi: 10.1111/j.1600-079X.2010.00792.x
Supplementary files
